30/01/2006 (Agence Europe) - At its meeting on 23-26 January, the European Medicines Agency's Committee for Medicinal Products for Human Use, for the first time as in new European pharmaceutical legislation, adopted a positive opinion for a similar biological medicinal product in the framework of the centralised placing on the market authorisation procedure. The product, Omnitrope, is manufactured by Sandoz GmbH and contains somatropin, a recombinant-DNA growth hormone. It is intended for...